


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on 1/12/00.

By: _____


Kendrick Nguyen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of James T. Kealey, et al.

Serial No.: 09/436,060

Examiner:

Filed: November 8, 1999

Art Unit:

COPY

For: INHIBITORY POLYNUCLEOTIDES DIRECTED AGAINST THE RNA
COMPONENT OF TELOMERASE

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

1. Transmitted herewith is:

☒ Information Disclosure Statement

☒ PTO Form 1449

☐ Copies of publications listed on the PTO Form 1449

☐ English translation of foreign language reference(s)

☒ No copies of publications listed on the PTO Form 1449 are being provided as this application claims continuation status to application Serial No. 08/770,564 and copies of the listed publications were provided in the parent application.

☐ Copy of foreign examination report

☐ English translation of foreign examination report

2. ☒ This Information Disclosure Statement is filed before the later of:
- ☒ three months from the filing date of this national application;
 - ☐ three months from the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or
 - ☐ the mailing date of a first office action on the merits.

In accordance with 37 CFR 1.97(b), no fee is required.

3. Fees


- ☐ Check in the amount of \$0.00 is attached.
- ☐ Please charge Deposit Account No. 03-3117 in the amount of \$0.00.
- ☒ No fee is required.
- ☒ The Commissioner is hereby authorized to charge any underpayment or credit any overpayment of the following fees associated with this communication to Deposit Account No. 03-3117:
 - ☒ Any patent application processing fees under 37 CFR 1.17.

Cooley Godward LLP
Attn: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000
Fax: (650) 857-0663
ML:kn
485782 v1/PA
@#TY01!.DOC

COPY

By:


Respectfully submitted,
COOLEY GODWARD LLP



Marcella Lillis, Ph.D.
Reg. No. 36,583

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on 1/11/00.

By: _____


Kendrick Nguyen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of James T. Kealey, et al.

Serial No.: 09/436,060

Examiner:

Filed: November 8, 1999

Art Unit:

COPY

For: INHIBITORY POLYNUCLEOTIDES DIRECTED AGAINST THE RNA
COMPONENT OF TELOMERASE

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicant hereby submits this Information Disclosure Statement in accordance with 37 CFR 1.98 and pursuant to Applicant's continuing duty under 37 CFR 1.56 to bring any information which may be material to patentability of this application to the Examiner's attention.

Applicant makes no representation that a search has been conducted by the Applicant, or that there is not possibly more relevant art. Applicant also makes no representation that the information submitted herewith is in fact material.

- [X] No copies enclosed: The publications listed on the enclosed Form PTO 1449 have been previously cited by or submitted to the PTO as recited in the Information Disclosure Statement Transmittal that accompanies this paper. In accordance with the provisions of 37 C.F.R. 1.98(d), no copies of these publications are being provided.

- ☐ Copies enclosed: Copies of the publications listed on the enclosed Form PTO 1449 are being provided with this Information Disclosure Statement.
- ☐ The enclosed publications were cited in a foreign examination report in a related case. A copy of the search report and the cited references are attached hereto.
- ☐ The search report is not in the English language and a translation of the search report is enclosed.
- ☐ At least one of the enclosed publications is not in the English language.
- ☐ English translation(s) are enclosed.
- ☐ Enclosed is an explanation of the relevance of non-English publications for which an English translation is not available.
- ☐ The explanation is in the form of an English language search report.

The subject application is believed patentable over any of the above references.

Cooley Godward LLP
Attn: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000
Fax: (650) 857-0663
ML:kn

COPY

Respectfully submitted,
COOLEY GODWARD LLP

By:



Marcella Lillis, Ph.D.
Reg. No. 36,583

Enclosures: 1. Form PTO 1449
2. Copies of references cited on Form PTO-1449

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)APPLICANT:
James T. Kealey, et al.FILING DATE
November 8, 1999

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	P1	5,583,016	10 Dec '96	Villeponteau et al.			
	P2	5,770,422	23 Jun '98	Collins			
	P3	5,776,679	07 Jul '98	Villeponteau et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	F1	WO 95/13381	18 May '95	PCT				
	F2	WO 96/01614	25 Jan '96	PCT				
	F3	WO 96/01835	25 Jan '96	PCT				
	F4	WO 96/40868	19 Dec '96	PCT				
	F5							

OTHER PUBLICATIONS (including Author, Title, Date, Pertinent Pages, Etc.)

	D1	Albanell et al., "Telomerase Activity Is Repressed During Differentiation of Maturation-Sensitive but Not Resistant Human Tumor Cell Lines," <i>Cancer Research</i> , 56:1503-1508 (1996)
	D2	Avilion et al., "Human Telomerase RNA and Telomerase Activity in Immortal Cell Lines and Tumor Tissues," <i>Cancer Research</i> , 56:645-650 (1996)
	D3	Blasco et al., "Functional Characterization and Developmental Regulation of Mouse Telomerase RNA," <i>Science</i> , 269:1267-1270 (1995)
	D4	Bodnar et al., "Mechanism of Telomerase Induction During T Cell Activation," <i>Experimental Cell Research</i> , 228:58-68, Article No. 0299 (1996)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

APPLICANT:

James T. Kealey, et al.

FILING DATE

November 8, 1999

GROUP

D5	Branch, <i>TIBS</i> , 23:45-50 (Feb 1998)
D6	Feng et al., "The RNA Component of Human Telomerase," <i>Science</i> , 269:1236-1241 (1995)
D7	Gewirtz et al., "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on Its Promise," <i>PNAS</i> , 93:3161 (Apr 1996)
D8	Harley et al., "Telomeres and Telomerase in Aging and Cancer," <i>Current Opinion in Genetics and Development</i> , 5:249-255 (1995)
D9	Hodgson, "Advances in Vector Systems for Gene Therapy," <i>Exp. Opin. Ther. Patents</i> , 5(5):459-468 (1995)
D10	Kim et al., "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer," <i>Science</i> , 266:2011-2015 (1994)
D11	Rojanasakul et al., "Antisense Oligonucleotide Therapeutics: Drug Delivery and Targeting," <i>Advanced Drug Delivery Reviews</i> , 18:115-131 (1996)
D12	Villeponteau, "The RNA Components of Human and Mouse Telomerases," <i>Seminars in Cell and Development Biology</i> , 7:15-21 (1996)
D13	
EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

485726 v1/PA
@#S#01!.DOC